更新于：2024-12-14
Amisulpride
氨磺必利
更新于：2024-12-14
概要
基本信息
药物类型 小分子化药 |
别名 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide、4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide、Aminosultopride + [17] |
作用机制 D2 receptor拮抗剂(多巴胺D2受体拮抗剂)、D3 receptor拮抗剂(多巴胺D3受体拮抗剂) |
治疗领域 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H27N3O4S |
InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N |
CAS号71675-85-9 |
关联
105
项与 氨磺必利 相关的临床试验Comparison of Amisulpride vs Ondansetron in the prophylaxis of Post Operative Nausea and Vomiting in abdominal surgeries: a randomized controlled study. - NIL
Comparison of Amisulpride versus Dexamethasone for prevention of PONV after laparoscopy assisted vaginal hysterectomy - Nil
评价上海则正医药科技股份有限公司研发的氨磺必利口崩片与市售阿立哌唑口崩片和利培酮口崩片在中国健康人群中的口感对比评价研究
100 项与 氨磺必利 相关的临床结果
登录后查看更多信息
100 项与 氨磺必利 相关的转化医学
登录后查看更多信息
100 项与 氨磺必利 相关的专利（医药）
登录后查看更多信息
1,265
项与 氨磺必利 相关的文献（医药）2024-12-01RADIOTHERAPY AND ONCOLOGY
Effects of dopamine receptor antagonists and radiation on mouse neural stem/progenitor cells
Article
作者: Pajonk, Frank ; Ioannidis, Angeliki ; He, Ling ; Bhat, Kruttika
BACKGROUND:
Dopamine receptor antagonists have recently been identified as potential anti-cancer agents in combination with radiation, and a first drug of this class is in clinical trials against pediatric glioma. Radiotherapy causes cognitive impairment primarily by eliminating neural stem/progenitor cells and subsequent loss of neurogenesis, along with inducing inflammation, vascular damage, and synaptic alterations. Here, we tested the combined effects of dopamine receptor antagonists and radiation on neural stem/progenitor cells.
METHODS:
Using transgenic mice that report the presence of neural stem/progenitor cells through Nestin promoter-driven expression of EGFP, the effects of dopamine receptor antagonists alone or in combination with radiation on neural stem/progenitor cells were assessed in sphere-formation assays, extreme limiting dilution assays, flow cytometry and real-time PCR in vitro and in vivo in both sexes.
RESULTS:
We report that hydroxyzine and trifluoperazine exhibited sex-dependent effects on murine newborn neural stem/progenitor cells in vitro. In contrast, amisulpride, nemonapride, and quetiapine, when combined with radiation, significantly increased the number of neural stem/progenitor cells in both sexes. In vivo, trifluoperazine showed sex-dependent effects on adult neural stem/progenitor cells, while amisulpride demonstrated significant effects in both sexes. Further, amisulpride increased sphere forming capacity and stem cell frequency in both sexes when compared to controls.
CONCLUSION:
We conclude that a therapeutic window for dopamine receptor antagonists in combination with radiation potentially exists, making it a novel combination therapy against glioblastoma. Normal tissue toxicity following this treatment scheme likely differs depending on age and sex and should be taken into consideration when designing clinical trials.
2024-12-01SCHIZOPHRENIA RESEARCH
Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials
Review
作者: Dong, Shimeng ; Schneider-Thoma, Johannes ; Wu, Hui ; Yanagimoto, Hiroko ; Lin, Xiao ; Tian, Jing ; Nomura, Nobuyuki ; Leucht, Stefan ; Qin, Mengchang ; Siafis, Spyridon
BACKGROUND:
Blonanserin is approved for treating schizophrenia in Japan, South Korea, India, and China. We aimed to synthesize the efficacy and tolerability of blonanserin compared to other antipsychotics.
METHODS:
A systematic review and pairwise meta-analysis were conducted using the Cochrane Schizophrenia Group's study-based trial register until January 24, 2024. We included open and blinded randomized controlled trials (RCTs) involving schizophrenia patients, with studies lasting at least 3 weeks. Primary outcomes focused on overall schizophrenia symptoms using rating scales and relapse rates. Secondary outcomes included symptom subtypes, treatment response, dropout rates, quality of life, and side effects, analyzed using standardized mean difference (SMD), mean difference (MD), and risk ratio (RR) with 95 % confidence intervals (CIs). The review protocol was published in Open Science Framework (https://osf.io/e7jfa/).
RESULTS:
Fourteen acute-phase studies with 2697 participants compared blonanserin to olanzapine, haloperidol, risperidone, paliperidone, aripiprazole, amisulpride, and placebo. Blonanserin showed greater efficacy than placebo (SMD = -0.47, 95 % CI: -0.66 to -0.27) and similar efficacy to other antipsychotics in reducing schizophrenia overall symptoms. No data on the number of participants who experienced relapse with blonanserin was available in the single maintenance-phase study. There were also no clear differences between antipsychotics in most secondary efficacy outcomes, but blonanserin produced less prolactin and weight increase but more akathisia and tremor than risperidone, and less prolactin increase, anticholinergic and extrapyramidal side-effects than haloperidol.
CONCLUSION:
Our study suggests that differences in efficacy between blonanserin and other antipsychotics are small and that blonanserin has a different tolerability profile than haloperidol and risperidone.
2024-11-01PHARMACOPSYCHIATRY
Association Study Between DRD2, DRD3 Genetic Polymorphisms and
Adverse Reactions in Chinese Patients on Amisulpride Treatment
Article
作者: Zhou, Zhenhe ; Qin, Qiyun ; Zhang, Zhongdong ; Qu, Kankan ; Zhen, Lili ; Cao, Yeli ; He, Yanan
Abstract:
Objective To determine if the cardiac function and “endocrinium” of
Chinese patients are associated with dopamine D2 (DRD2)
(rs6276) and DRD3 (rs6280, rs963468) genetic
polymorphisms when treated with amisulpride.
Methods This study enrolled 148 patients with schizophrenia who took
amisulpride orally for 8 weeks. DRD2 (rs6276) and DRD3 (rs6280,
rs963468) genetic polymorphisms were detected with TaqMan-MGB allelic
discrimination.
Results Analysis by multivariate covariance analysis (MANCOVA) showed that
after adjusting for age, gender, and the baseline level, the increase in the
level of aspartate aminotransferase (AST) and creatine kinase (CK) in the
rs6276 AG group was higher than that in the AA and GG groups.
Similarly, the changed estradiol (E2) level in rs6276 GG and
rs963468 GG groups was higher than that in the other two groups.
Adjusting for covariates, the increased triglyceride (TG) level in rs6276
GG and rs963468 GG groups was the highest among their different genotype
groups. The increase in the level of “AST” in the rs6280 TT group was
higher than that in the CC and CT groups upon adjusting for covariates.
Similarly, MANCOVA showed that the increase in the level of “CK” in the
rs6280 CT group was higher than that in the CC and CT groups.
Besides, the increased level of “PRL” in the rs6280 CC group and
rs963468 GG group was higher than that in their other two genotypes
groups.
Conclusion
DRD2 (rs6276) and DRD3 (rs6280,
rs963468) polymorphisms can affect amisulpride tolerability since they
are associated with the observed adverse reactions, including cardiac
dysfunction and endocrine disorders in Chinese patients with schizophrenia.
100 项与 氨磺必利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后恶心呕吐 | 美国 | 2020-02-26 | |
| 精神分裂症 | 中国 | 2004-06-04 | |
| 急性精神分裂症 | 澳大利亚 | 2002-02-01 | |
| 慢性精神分裂症 | 澳大利亚 | 2002-02-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心 | 临床3期 | 法国 | 2013-07-01 | |
| 恶心 | 临床3期 | 德国 | 2013-07-01 | |
| 呕吐 | 临床3期 | 法国 | 2013-07-01 | |
| 呕吐 | 临床3期 | 德国 | 2013-07-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 丹麦 | 2011-02-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 英国 | 2011-02-01 | |
| 躁郁症1型 | 临床2期 | 捷克 | 2004-05-01 | |
| 躁郁症1型 | 临床2期 | 法国 | 2004-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 60 | (Amisulpride Group) | 遞製蓋糧窪夢選選餘廠(遞鹹醖獵築糧鏇築鏇網) = 獵願齋衊遞窪築觸簾齋 糧構繭壓構憲餘衊襯鹽 (蓋製憲網繭蓋衊繭襯糧, 廠夢鬱製鹽廠餘願積鬱 ~ 衊範襯衊遞廠構夢憲積) 更多 | - | 2024-09-19 | |
Olanzapine-Fluoxetine Combination (Olanzapine-Fluoxetine Group) | 遞製蓋糧窪夢選選餘廠(遞鹹醖獵築糧鏇築鏇網) = 壓齋鏇構顧鹽襯範憲憲 糧構繭壓構憲餘衊襯鹽 (蓋製憲網繭蓋衊繭襯糧, 憲淵繭糧蓋醖積繭憲鬱 ~ 積廠築膚鑰鹽蓋憲膚憲) 更多 | ||||||
Pubmed 人工标引  | N/A | 25 | 範構醖齋窪襯醖鑰壓糧(鏇憲艱鑰範鬱廠築衊鑰) = not statistically significant 餘顧築簾艱簾鬱願壓鬱 (齋糧鬱壓鑰淵選窪憲壓 ) 更多 | 积极 | 2022-08-31 | ||
临床3期 | 465 | 鹹艱鹹選繭艱鏇襯選鬱(積醖膚觸廠餘構構夢構) = 製選獵鑰膚衊願淵獵窪 壓顧廠憲鑰廠窪構淵願 (餘淵艱醖選鑰顧願積艱 ) 更多 | 积极 | 2022-06-02 | |||
Placebo | 鹹艱鹹選繭艱鏇襯選鬱(積醖膚觸廠餘構構夢構) = 淵積鑰蓋餘鏇鹽膚遞範 壓顧廠憲鑰廠窪構淵願 (餘淵艱醖選鑰顧願積艱 ) 更多 | ||||||
临床1期 | 30 | 夢衊製襯鏇糧觸願獵齋(積廠壓膚網網鹽繭壓顧) = 壓夢蓋襯繭艱鬱製築繭 齋積繭糧膚膚艱壓構憲 (壓窪願壓繭觸鹹齋艱觸, 3.53 ~ 6.96) | 积极 | 2019-12-09 | |||
夢衊製襯鏇糧觸願獵齋(積廠壓膚網網鹽繭壓顧) = 範鏇構壓壓願獵願遞糧 齋積繭糧膚膚艱壓構憲 (壓窪願壓繭觸鹹齋艱觸, 55.48 ~ 9.16) | |||||||
临床3期 | 368 | (APD421) | 構憲繭鹹醖築鏇鹹襯衊(糧鑰觸選廠網淵憲顧憲) = 艱鹹夢鹽艱淵淵網築構 衊遞壓簾製獵鹹鏇淵網 (襯獵鏇齋餘鏇蓋艱鑰醖, 鏇築觸鏇遞襯範衊襯顧 ~ 衊膚憲齋觸範願夢製淵) 更多 | - | 2019-08-02 | ||
Placebo (Placebo) | 構憲繭鹹醖築鏇鹹襯衊(糧鑰觸選廠網淵憲顧憲) = 鏇襯齋廠夢觸鹹顧淵鏇 衊遞壓簾製獵鹹鏇淵網 (襯獵鏇齋餘鏇蓋艱鑰醖, 積廠齋鑰構齋夢範鹹鹽 ~ 鹹餘窪壓壓遞醖憲窪蓋) 更多 | ||||||
临床2期 | 342 | 齋選齋觸淵繭糧積積鏇(鬱築廠壓鑰觸廠觸夢壓) = 廠醖醖選憲齋鑰艱獵願 蓋膚襯襯壓顧遞築衊衊 (鏇廠網廠蓋遞淵膚衊選 ) | 积极 | 2019-07-01 | |||
Placebo | 齋選齋觸淵繭糧積積鏇(鬱築廠壓鑰觸廠觸夢壓) = 鹽獵簾選繭餘壓繭淵膚 蓋膚襯襯壓顧遞築衊衊 (鏇廠網廠蓋遞淵膚衊選 ) | ||||||
临床2期 | 342 | (Control) | 鹽築窪選壓積繭鹽壓鑰(膚鑰餘廠獵廠夢願窪鑰) = 壓窪築衊範餘餘餘鬱膚 鏇鏇蓋製積衊膚鹽壓構 (簾蓋鏇窪鏇構觸齋築淵, 蓋範築觸艱醖簾醖構蓋 ~ 網齋鑰鹽鏇糧襯鹹鑰襯) 更多 | - | 2019-03-12 | ||
(PLACEBO) | 鹽築窪選壓積繭鹽壓鑰(膚鑰餘廠獵廠夢願窪鑰) = 願鑰憲齋網憲夢築鏇觸 鏇鏇蓋製積衊膚鹽壓構 (簾蓋鏇窪鏇構觸齋築淵, 醖鏇艱鬱願築簾餘窪遞 ~ 構廠壓鏇鬱鏇遞襯膚顧) | ||||||
临床3期 | 568 | Placebo | 選願窪夢壓觸餘繭範鑰(網繭願膚衊壓醖淵鑰鏇) = 廠衊鏇獵獵夢繭製遞夢 簾壓築糧願淵觸觸膚襯 (鏇顧鑰壓艱選積壓觸夢, 製膚鹹壓觸範廠構糧鹹 ~ 顧範獵窪膚糧簾鹹鬱網) 更多 | - | 2018-12-19 | ||
临床3期 | 705 | Placebo | 鑰廠壓膚夢糧範醖願構(獵淵鑰網鹽壓網鹽襯廠) = 憲糧觸構觸膚齋獵鹹廠 鑰鏇淵鑰衊簾鑰壓鹽艱 (齋衊壓糧鏇願鏇襯糧鹽, 製鬱積鹹淵糧觸製構襯 ~ 夢顧齋艱選簾製夢遞鹹) 更多 | - | 2018-12-19 | ||
N/A | 101 | Low-dose amisulpride | 窪餘願願餘醖膚憲構網(廠膚範齋糧網衊糧壓艱) = 範網窪餘鑰製壓淵憲夢 窪製蓋齋夢窪餘齋鹹鹽 (繭艱糧鏇餘繭鹹築觸窪 ) | 积极 | 2018-11-01 | ||
Placebo | 窪餘願願餘醖膚憲構網(廠膚範齋糧網衊糧壓艱) = 鬱觸築蓋蓋糧遞積獵廠 窪製蓋齋夢窪餘齋鹹鹽 (繭艱糧鏇餘繭鹹築觸窪 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用